These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24033561)

  • 21. Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty.
    Swaiss HH; Khawaja NM; Farahid OH; Batieha AM; Ajlouni KM
    Saudi Med J; 2017 Nov; 38(11):1101-1107. PubMed ID: 29114697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The effect of treatment on growth in children with central precocious puberty].
    Snajderová M; Zemková D; Lebl J; Kolousková S
    Cas Lek Cesk; 1995 Mar; 134(6):173-5. PubMed ID: 7758068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.
    Roth CL; Brendel L; Rückert C; Hartmann K
    Horm Res; 2005; 63(5):257-62. PubMed ID: 15995342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term therapy of central precocious puberty in girls with the gonadoliberin analog D-Trp-6-LHRH after prior therapy with cyproterone acetate].
    Snajderová M; Zemková D; Lebl J; Pechová M; Zounarová M; Kolousková S
    Cesk Pediatr; 1994; 49(1):29-33. PubMed ID: 8124747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty.
    Seminara S; Nanni L; Generoso M; Mirri S; Leonardi V; Slabadzianiuk T; Vetrano ML; Buongiorno A; Losi S; Galluzzi F
    Horm Res Paediatr; 2010; 73(5):386-9. PubMed ID: 20389110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents.
    Iannetta R; Melo AS; Iannetta O; Marchini JS; Paula FJ; Martinelli CE; Rosa e Silva AC; Ferriani RA; Martins WP; Reis RM
    J Pediatr Adolesc Gynecol; 2015 Oct; 28(5):304-8. PubMed ID: 26081481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin.
    Bertelloni S; Massart F; Einaudi S; Wasniewska M; Miccoli M; Baroncelli GI
    Horm Res Paediatr; 2015; 84(6):396-400. PubMed ID: 26528763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty.
    Laron Z; Kauli R; Zeev ZB; Comaru-Schally AM; Schally AV
    Lancet; 1981 Oct; 2(8253):955-6. PubMed ID: 6117727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Improvement of expected and final height in girls with central precocious puberty treated with gonadotropin releasing hormone analogues].
    Gómez F; Picó AM; Vargas F; Mauri M
    Med Clin (Barc); 1996 Nov; 107(18):681-4. PubMed ID: 9082075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid outcome during long-term gonadotropin-releasing hormone agonist treatments for idiopathic precocious puberty.
    Massart F; Harrell JC; Federico G; Saggese G
    J Adolesc Health; 2007 Mar; 40(3):252-7. PubMed ID: 17321426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with gonadotropin-releasing hormone analogues: different impact on body weight in normal-weight and overweight children.
    Wolters B; Lass N; Reinehr T
    Horm Res Paediatr; 2012; 78(5-6):304-11. PubMed ID: 23257624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.